The potential economic value of a therapeutic Chagas disease vaccine for pregnant women to prevent congenital transmission
- 12 March 2020
- journal article
- research article
- Published by Elsevier BV in Vaccine
- Vol. 38 (16), 3261-3270
- https://doi.org/10.1016/j.vaccine.2020.02.078
Abstract
No abstract availableFunding Information
- Agency for Healthcare Research and Quality
- Office of Behavioral and Social Sciences Research
- Eunice Kennedy Shriver National Institute of Child Health and Human Development
- United States Agency for International Development
This publication has 63 references indexed in Scilit:
- Achievements and Challenges upon the Implementation of a Program for National Control of Congenital Chagas in Bolivia: Results 2004–2009PLoS Neglected Tropical Diseases, 2013
- A Phase 3 Trial of RTS,S/AS01 Malaria Vaccine in African InfantsThe New England Journal of Medicine, 2012
- Risk Factors and Primary Prevention of Congenital Chagas Disease in a Nonendemic CountryClinical Infectious Diseases, 2012
- Congenital Chagas Disease: Recommendations for Diagnosis, Treatment and Control of Newborns, Siblings and Pregnant WomenPLoS Neglected Tropical Diseases, 2011
- The Potential Economic Value of a Trypanosoma cruzi (Chagas Disease) Vaccine in Latin AmericaPLoS Neglected Tropical Diseases, 2010
- Clinical Benefits, Costs, and Cost-Effectiveness of Neonatal Intensive Care in MexicoPLoS Medicine, 2010
- Congenital Trypanosoma cruzi Infection. Efficacy of Its Monitoring in an Urban Reference Health Center in a Non-Endemic Area of ArgentinaThe American Journal of Tropical Medicine and Hygiene, 2010
- Constructing target product profiles (TPPs) to help vaccines overcome post-approval obstaclesVaccine, 2010
- Antibody drop in newborns congenitally infected byTrypanosoma cruzitreated with benznidazoleTropical Medicine & International Health, 2009
- Epidemiology and causes of preterm birthThe Lancet, 2008